pepgen.com (PEPG) Year-over-year earnings per share growth for the last twelve months
PepGen Inc. targets the Duchenne muscular dystrophy therapy market, where the cost of innovation is borne by healthcare systems and insurers. The quarterly EPS trajectory reflects market expectations, while the value of 46.80 describes the current level of this metric. The company's prospects rely on the diversification of peptide developments and a strategy to advance key molecules to Phase 2 trials.
Comprehensive metric breakdowns and analytics for PepGen Inc. (PEPG)
- share price and expert price forecast:
- market capitalization details:
- book capitalization data:
- debt and solvency information:
- earnings and valuation multiples information:
PEPG - Company Net Income|Expected Profit PepGen Inc.|PEPG - Market Cap to Net Income|Forward P/E Multiple pepgen.com|PEPG - Price to Net Income Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Corp|PEPG - Operating profit before amortization|Net earnings per share (EPS TTM) PepGen|PEPG - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months pepgen.com|PEPG - Earnings growth in current year|Net earnings per share growth forecast for next year PepGen Inc.
- sales revenue and business income indicators:
Basic company analysis:PepGen Inc, PEPG
For PepGen Inc. (PEPG), whose market capitalization depends on clinical trial outcomes and R&D spending efficiency, the quarterly EPS growth trajectory reflects the dynamics of net income per share. This indicator measures the rate of change in the bottom line, allowing investors to assess the quality of capital management and the risk of overpaying for the asset in the absence of operating revenue.
Competitors of PepGen Inc. (PEPG)
BIIB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurocrine (NBIX)|Year-over-year earnings per share growth for the last twelve months Regencell|Year-over-year earnings per share growth for the last 12 months AXSM (Axsome Corp)|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals)|XENE (xenon-pharma.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth VKTX (Viking Therapeutics, Inc.)|Year-over-year net earnings per share change for the last twelve months Supernus Pharmaceuticals, Inc. (SUPN)|CPRX - Year-over-year earnings per share growth for the last twelve months|DNLI (Denali Corp) - Year-over-year earnings per share growth for the last 12 months|HRMY: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months biohavenpharma.com|Year-over-year net earnings per share growth for the last 12 months AMLX|Trevi Therapeutics Inc (TRVI) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Praxis Medicines (PRAX)|AVXL: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth CBLL (CeriBell, Inc.)|prothena.com (PRTA) - Earnings per share growth in annualized terms for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months ANNX|OMER: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Neurogene Therapeutics NGNE|Year-over-year earnings per share growth for the last twelve months AC Immune|Year-over-year earnings per share growth for the last 12 months VYGR (voyagertherapeutics.com)|Quarterly EPS earnings growth NMRA|SCLX - Earnings per share growth in annualized terms for the last twelve months|Tevogen Bio Holdings, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Alpha Cognition Inc ACOG|CGTX - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months IKT (inhibikase.com)|Cassava Sciences (SAVA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Assertio (ASRT)|Year-over-year earnings per share growth for the last twelve months Coya Therapeutics Inc|VistaGen Therapeutics Inc - Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth OVID|ABOS - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months CervoMed CRVO|ATHE (Alterity Therapeutics Ltd.) - Year-over-year net earnings per share trend for the last twelve months|Clene Nanomedicine - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year jupiterneurosciences.com (JUNS)|RLMD: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months annovisbio.com (ANVS)|Year-over-year earnings per share growth for the last twelve months Grace Therapeutics Inc|Year-over-year earnings per share growth for the last 12 months AIFF (Firefly Neuroscience, Inc.)|Year-over-year net earnings per share growth for the last 12 months KLTO (Klotho Neurosciences Inc)|NRSN (neurosense-tx.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth RVPH (Reviva Pharmaceuticals)|Year-over-year net earnings per share change for the last twelve months MetaVia Inc. (MTVA)|NRXS - Year-over-year earnings per share growth for the last twelve months|HSDT (Helius Medical) - Year-over-year earnings per share growth for the last 12 months|PASG: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Neuphoria Therapeutics|Year-over-year net earnings per share growth for the last 12 months NERV|athira.com (ATHA) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Addex Therapeutics Ltd (ADXN)|ALZN: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth CYCN (Cyclerion Therapeutics, Inc.)|Protagenic Therapeutics Inc. (PTIX) - Earnings per share growth in annualized terms for the last twelve months|KTTA - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months CRGT|ATXI: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Brainstorm Cell Therapeutics Inc. BCLI|Year-over-year earnings per share growth for the last twelve months Cara Therapeutics, Inc|Year-over-year earnings per share growth for the last 12 months CHRO (Chromocell)|Quarterly EPS earnings growth ELYM|ITCI - Earnings per share growth in annualized terms for the last twelve months|Longboard Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Marinus Pharmaceuticals Inc MRNS|NKGN - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months NRBO (NeuroBo Pharma)|Sage Therapeutics, Inc. (SAGE) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months synaptogen.com (SNPX)|Year-over-year earnings per share growth for the last twelve months Trevena|Vigil Neuro - Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth WENA|CERE - Earnings per share growth in annualized terms for the last twelve months
